Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Update

$SeaStar Medical (ICU.US)$ SeaStar Medical Estimates US Total Addressable Market For Its Proprietary, Patented Selective Cytopheretic Device In Five Clinical Indications Of $25B - $33B
Benzinga· 5 mins ago
The SCD has been awarded FDA Breakthrough Device Designation (BDD) in three of the five indications included in the chart above, namely adult AKI, hepatorenal syndrome and cardiorenal syndrome with LVAD. The SCD was also awarded BDD for chronic dialysis in November 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
28
Translate
Report
2549 Views
Comment
Sign in to post a comment

View more comments...